Nonalcoholic Steatohepatitis

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

May 19, 2015
popularity 20 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Hacking the nervous system

When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that ...

Brain signals contain the code for your next move

Is it possible to tap into the signalling in the brain to figure out where you will go next? Hiroshi Ito, a researcher at the Kavli Institute for Systems Neuroscience at the Norwegian University of Science ...

Diagnosing cancer with help from bacteria

Engineers at MIT and the University of California at San Diego (UCSD) have devised a new way to detect cancer that has spread to the liver, by enlisting help from probiotics—beneficial bacteria similar to ...